JP2016512960A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512960A5
JP2016512960A5 JP2015560341A JP2015560341A JP2016512960A5 JP 2016512960 A5 JP2016512960 A5 JP 2016512960A5 JP 2015560341 A JP2015560341 A JP 2015560341A JP 2015560341 A JP2015560341 A JP 2015560341A JP 2016512960 A5 JP2016512960 A5 JP 2016512960A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
talen
gene
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015560341A
Other languages
English (en)
Japanese (ja)
Other versions
JP6480874B2 (ja
JP2016512960A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/019322 external-priority patent/WO2014134412A1/en
Publication of JP2016512960A publication Critical patent/JP2016512960A/ja
Publication of JP2016512960A5 publication Critical patent/JP2016512960A5/ja
Priority to JP2019021260A priority Critical patent/JP6893945B2/ja
Application granted granted Critical
Publication of JP6480874B2 publication Critical patent/JP6480874B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015560341A 2013-03-01 2014-02-28 Talenに基づく遺伝子修正 Expired - Fee Related JP6480874B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019021260A JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361771735P 2013-03-01 2013-03-01
US61/771,735 2013-03-01
PCT/US2014/019322 WO2014134412A1 (en) 2013-03-01 2014-02-28 Talen-based gene correction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019021260A Division JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正

Publications (3)

Publication Number Publication Date
JP2016512960A JP2016512960A (ja) 2016-05-12
JP2016512960A5 true JP2016512960A5 (https=) 2017-03-30
JP6480874B2 JP6480874B2 (ja) 2019-03-13

Family

ID=51428832

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015560341A Expired - Fee Related JP6480874B2 (ja) 2013-03-01 2014-02-28 Talenに基づく遺伝子修正
JP2019021260A Expired - Fee Related JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正
JP2021015441A Pending JP2021088565A (ja) 2013-03-01 2021-02-03 Talenに基づく遺伝子修正

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019021260A Expired - Fee Related JP6893945B2 (ja) 2013-03-01 2019-02-08 Talenに基づく遺伝子修正
JP2021015441A Pending JP2021088565A (ja) 2013-03-01 2021-02-03 Talenに基づく遺伝子修正

Country Status (7)

Country Link
US (4) US9393257B2 (https=)
EP (2) EP2961262B1 (https=)
JP (3) JP6480874B2 (https=)
AU (2) AU2014223243B2 (https=)
CA (1) CA2902954A1 (https=)
ES (1) ES2750550T3 (https=)
WO (1) WO2014134412A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9850497B2 (en) * 2013-11-04 2017-12-26 Regents Of The University Of Minnesota Gene targeting methods and tools
ES2939542T3 (es) 2014-01-31 2023-04-24 Factor Bioscience Inc Métodos y productos para la producción y la administración de ácido nucleico
WO2016081518A2 (en) 2014-11-17 2016-05-26 Adicet Bio, Inc. Engineered gamma delta t-cells
JP7199809B2 (ja) 2015-02-13 2023-01-06 ファクター バイオサイエンス インコーポレイテッド 核酸製品及びその投与方法
CN104726495B (zh) * 2015-03-25 2018-06-19 西北农林科技大学 一种基于talen介导的基因打靶敲除山羊blg的载体及重组细胞
KR20250171479A (ko) 2015-03-31 2025-12-08 소흠, 인코포레이티드 세포 또는 유기체의 게놈으로의 DNA 서열의 표적화 혼입을 위한 Cas 9 레트로바이러스 인테그라제 시스템 및 Cas 9 재조합효소 시스템
EP3292219B9 (en) 2015-05-04 2022-05-18 Ramot at Tel-Aviv University Ltd. Methods and kits for fragmenting dna
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
US20180296600A1 (en) * 2015-10-27 2018-10-18 The Board Of Trustees Of The Leland Stanford Junior University Treatment of epidermolysis bullosa by injection of autologous collagen vii overexpressing leukocytes
PT3377637T (pt) 2016-04-08 2020-06-17 Krystal Biotech Inc Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
EP3454870A4 (en) 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
JP2020513754A (ja) 2016-12-21 2020-05-21 ティーシーアール2 セラピューティクス インク. がん治療用に操作されたt細胞
WO2018140497A1 (en) 2017-01-25 2018-08-02 Efimov Igor R Apparatus and methods for in vitro preclinical human trials
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
EP3585897A1 (en) * 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
WO2018229226A1 (en) 2017-06-14 2018-12-20 Technische Universität Dresden Methods and means for genetic alteration of genomes utilizing designer dna recombining enzymes
US20200206272A1 (en) 2017-06-19 2020-07-02 National University Corporation Hokkaido University Treatment agent for epidermolysis bullosa
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
WO2019099744A1 (en) 2017-11-15 2019-05-23 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
CA3094345A1 (en) 2018-04-12 2019-10-17 Krystal Biotech, Inc. Compositions and methods for the treatment of autosomal recessive congenital ichthyosis
WO2019204226A1 (en) 2018-04-16 2019-10-24 University Of Massachusetts Compositions and methods for improved gene editing
SG11202009895TA (en) 2018-04-27 2020-11-27 Krystal Biotech Inc Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
WO2019217837A1 (en) 2018-05-11 2019-11-14 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
EP3800998A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Methods of regenerating and transforming cannabis
US12497593B2 (en) 2018-09-07 2025-12-16 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
EP3856761A1 (en) 2018-09-24 2021-08-04 Krystal Biotech, Inc. Compositions and methods for the treatment of netherton syndrome
WO2020112860A1 (en) 2018-11-30 2020-06-04 Intima Bioscience, Inc. Methods of identifying immunomodulatory genes
WO2020117862A1 (en) 2018-12-03 2020-06-11 Adicet Bio, Inc. Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof
WO2020163703A1 (en) 2019-02-08 2020-08-13 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
SG11202110956RA (en) 2019-04-05 2021-10-28 Rootpath Genomics Inc Compositions and methods for t-cell receptor gene assembly
WO2020252455A1 (en) 2019-06-13 2020-12-17 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
WO2020257553A1 (en) 2019-06-20 2020-12-24 Memorial Sloan-Kettering Cancer Center T cell receptors targeting pik3ca mutations and uses thereof
WO2020257684A1 (en) 2019-06-20 2020-12-24 University Of Massachusetts Compositions and methods for improved gene editing
JP7699552B2 (ja) 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
US20220267737A1 (en) 2019-07-18 2022-08-25 University Of Rochester Cell-type selective immunoprotection of cells
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
JP7831937B2 (ja) 2019-09-03 2026-03-17 クリエイト・メディシンズ,インコーポレーテッド ゲノム組込みのための方法および組成物
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN116133679A (zh) 2020-06-30 2023-05-16 门德斯有限公司 白血病衍生细胞在卵巢癌疫苗中的用途
EP4185600A4 (en) 2020-07-24 2024-12-04 The General Hospital Corporation Enhanced virus-like particles and methods of use thereof for delivery to cells
WO2022051418A1 (en) 2020-09-01 2022-03-10 64-X, Inc. Mammalian cells and methods for engineering the same
WO2022087380A1 (en) 2020-10-23 2022-04-28 Rootpath Genomics, Inc. Compositions and methods for t-cell receptor identification
WO2022155500A1 (en) 2021-01-14 2022-07-21 Senti Biosciences, Inc. Secretable payload regulation
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
KR20230157388A (ko) 2021-03-12 2023-11-16 멘두스 비.브이. 백신접종의 방법 및 cd47 차단의 용도
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
AU2022272235A1 (en) 2021-05-11 2023-12-21 Create Medicines, Inc. Methods and compositions for genomic integration
EP4430206A1 (en) 2021-11-10 2024-09-18 Encodia, Inc. Methods for barcoding macromolecules in individual cells
EP4493681A4 (en) 2022-03-17 2026-04-08 Keshihua Nanjing Biotechnology Co Ltd Tumor-Infiltrating Synthetic Lymphocytes (TILS)
WO2024039576A2 (en) 2022-08-19 2024-02-22 Memorial Sloan-Kettering Cancer Center T cell receptors targeting ras mutations and uses thereof
JP2025537861A (ja) 2022-11-18 2025-11-20 京都府公立大学法人 マイトファジー誘導のための組成物およびその使用
WO2025128981A1 (en) 2023-12-14 2025-06-19 Sohm, Inc. Compositions and methods for genome editing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002099070A2 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
AU2010360293B2 (en) * 2010-09-06 2016-06-16 Temasek Life Sciences Laboratory Limited Molecular interaction between Xa10 and AvrXa10
EP3260540A1 (en) * 2010-11-12 2017-12-27 The General Hospital Corporation Polycomb-associated non-coding rnas
AU2012312260B2 (en) * 2011-09-21 2017-08-31 Sangamo Therapeutics, Inc. Methods and compositions for regulation of transgene expression

Similar Documents

Publication Publication Date Title
JP2016512960A5 (https=)
McCutcheon et al. Epigenome editing technologies for discovery and medicine
CN107208078B (zh) 使用成对向导rna进行靶向遗传修饰的方法和组合物
US10294494B2 (en) Methods and compositions for modifying a targeted locus
Gratz et al. CRISPR‐Cas9 genome editing in Drosophila
Puchta Using CRISPR/Cas in three dimensions: towards synthetic plant genomes, transcriptomes and epigenomes
US10858662B2 (en) Genome editing with split Cas9 expressed from two vectors
JP2017070287A5 (https=)
JP2016500262A5 (https=)
JP2016027807A5 (https=)
EP4407034A3 (en) Compositions and methods for modifying genomes
JP2018530336A5 (https=)
JP2016521993A5 (https=)
FI3690056T3 (fi) Menetelmiä ja tuotteita nukleiinihapon valmistamiseksi ja viemiseksi
MY197523A (en) Compositions and methods for modifying genomes
EP4310196A3 (en) Methods and compositions for manipulating nucleic acids
JP2020519304A5 (https=)
Hu et al. Targeting human microRNA genes using engineered Tal-effector nucleases (TALENs)
FI3445388T3 (fi) Materiaaleja ja menetelmiä hemoglobinopatioiden hoitamiseksi
Gibson et al. What rheumatologists need to know about CRISPR/Cas9
JP2020511931A5 (https=)
Yin et al. Multiplex conditional mutagenesis in zebrafish using the CRISPR/Cas system
Guo et al. Target site recognition by a diversity-generating retroelement
Wiegand et al. Efficient generation of gene knockout plasmids for Dictyostelium discoideum using one-step cloning
Lakhotia Central dogma, selfish DNA and noncoding Rnas: A historical perspective